GDUFA II User Fees. Update on Implementation

Size: px
Start display at page:

Download "GDUFA II User Fees. Update on Implementation"

Transcription

1 GDUFA II User Fees Update on Implementation Donal Parks, Director Division of User Fee Management and Budget Formulation OM CDER US FDA November 8, 2017

2 Outline Refresher on GDUFA II fee structure What stays the same What is new and different Preparations for GDUFA II fees Contract Manufacturing Organization (CMO) facility fee Generic Drug Applicant Program Fee (program fee) Implications for future years 2

3 Where We Ended GDUFA I Fee Type Target Percentage Total Target Revenue ANDA / PAS 24% $77,523,000 API Facility 14% $45,221,000 FDF Facility 56% $180,886,000 DMF 6% $19,381,000 Total: 100% $323,011,000 3

4 Where We Began GDUFA II Fee Type Target Percentage Total Target Revenue GDUFA I GDUFA II GDUFA I GDUFA II GDUFA I GDUFA II ANDA / PAS ANDA 24% 33% $77,523,000 $162,888,000 Program 35% $172,760,000 API Fac API Fac 14% 7% $45,221,000 $34,552,000 FDF Fac FDF Fac 56% 20% $180,886,000 $98,720,000 DMF DMF 6% 5% $19,381,000 $24,680,000 Total: 100% 100% $323,011,000 $493,600,000 4

5 Where We Began GDUFA II Fee Type Target Percentage Total Target Revenue GDUFA I GDUFA II GDUFA I GDUFA II GDUFA I GDUFA II ANDA / PAS ANDA 24% 33% $77,523,000 $162,888,000 Fee is due upon submission of an ANDA Withdraw before filing eligible for 75% refund State entities exempt from fee Program 35% $172,760,000 API Fac API Fac 14% 7% $45,221,000 $34,552,000 FDF Fac FDF Fac 56% 20% $180,886,000 $98,720,000 DMF DMF 6% 5% $19,381,000 $24,680,000 Total: 100% 100% $323,011,000 $493,600,000 5

6 Where We Began GDUFA II Fee Type Target Percentage Total Target Revenue GDUFA I GDUFA II GDUFA I GDUFA II GDUFA I GDUFA II ANDA / PAS ANDA 24% 33% $77,523,000 $162,888,000 Program 35% $172,760,000 API Fac API Fac 14% 7% $45,221,000 $34,552,000 Annual fee for holders of approved ANDAs FDF Fac FDF Fac 56% 20% $180,886,000 $98,720,000 DMF DMF 6% 5% $19,381,000 $24,680,000 Total: 100% 100% $323,011,000 $493,600,000 6

7 Where We Began GDUFA II Fee Type Target Percentage Total Target Revenue GDUFA I GDUFA II GDUFA I GDUFA II GDUFA I GDUFA II ANDA / PAS ANDA 24% 33% $77,523,000 $162,888,000 Program 35% $172,760,000 API Fac API Fac 14% 7% $45,221,000 $98,720,000 Together, the ANDA and Program fees under GDUFA II account for 68% of total revenue, up from 24% under GDUFA I FDF Fac FDF Fac 56% 20% $180,886,000 $34,552,000 DMF DMF 6% 5% $19,381,000 $24,680,000 Total: 100% 100% $323,011,000 $493,600,000 7

8 Where We Began GDUFA II Fee Type Target Percentage Total Target Revenue GDUFA I GDUFA II GDUFA I GDUFA II GDUFA I GDUFA II ANDA / PAS ANDA 24% 33% $77,523,000 $162,888,000 Fee due if referenced in approved application as of beginning of fiscal year Foreign facility fee differential of $15,000 Only one fee assessed Introduction of CMO fee Program 35% $172,760,000 API Fac API Fac 14% 7% $45,221,000 $98,720,000 FDF Fac FDF Fac 56% 20% $180,886,000 $34,552,000 DMF DMF 6% 5% $19,381,000 $24,680,000 Total: 100% 100% $323,011,000 $493,600,000 8

9 Where We Began GDUFA II Fee Type Target Percentage Total Target Revenue GDUFA I GDUFA II GDUFA I GDUFA II GDUFA I GDUFA II ANDA / PAS ANDA 24% 33% $77,523,000 $162,888,000 Together, facility fees under GDUFA II account for 27% of total revenue, down from 70% under GDUFA I Program 35% $172,760,000 API Fac API Fac 14% 7% $45,221,000 $98,720,000 FDF Fac FDF Fac 56% 20% $180,886,000 $34,552,000 DMF DMF 6% 5% $19,381,000 $24,680,000 Total: 100% 100% $323,011,000 $493,600,000 9

10 Where We Began GDUFA II Fee Type Target Percentage Total Target Revenue GDUFA I GDUFA II GDUFA I GDUFA II GDUFA I GDUFA II ANDA / PAS ANDA 24% 33% $77,523,000 $162,888,000 DMF fee due on first reference or request for CA Program 35% $172,760,000 API Fac API Fac 14% 7% $45,221,000 $34,552,000 FDF Fac FDF Fac 56% 20% $180,886,000 $98,720,000 DMF DMF 6% 5% $19,381,000 $24,680,000 Total: 100% 100% $323,011,000 $493,600,000 10

11 Where We Began GDUFA II Fee Type Target Percentage Total Target Revenue GDUFA I GDUFA II GDUFA I GDUFA II GDUFA I GDUFA II ANDA / PAS ANDA 24% 33% $77,523,000 $162,888,000 Finally, notice that there was a slight uptick in the size of the program Program 35% $172,760,000 API Fac API Fac 14% 7% $45,221,000 $34,552,000 FDF Fac FDF Fac 56% 20% $180,886,000 $98,720,000 DMF DMF 6% 5% $19,381,000 $24,680,000 Total: 100% 100% $323,011,000 $493,600,000 11

12 Top Challenges in GDUFA II Fees CMO Fee Not clear how many facilities would qualify Affiliations with sponsors Generic Drug Applicant Program Fee Unknown affiliations Inactive ANDAs Portfolio adjustments 12

13 CMO Fee A contract manufacturing organization is a facility that provides FDF manufacturing services under contract to ANDA holders with which it is not affiliated. The CMO fee is one-third the fee assessed to an FDF facility. 13

14 How We Estimated CMOs Pulled data from Integrity Services (IS) Cross-checked with other data sources Facility Self-Identification data GDUFA I payment data FDA Establishment Identifier (FEI) information Facility history report 14

15 So What Did We Come Up With? As published in the Federal Register on August 29, 2017 Domestic CMO 71 Foreign CMO 97 Total Fees were calculated to be Domestic CMO - $70,362 Foreign CMO - $85,362 15

16 Experience So Far Of the 168 CMO facilities we expected to see: 124 facilities incurred and paid the CMO fees 6 facilities incurred FDF fees but paid CMO fees 20 facilities incurred CMO fees but paid FDF fees 18 facilities paid CMO fees but are pending CMO validations Note: These data are as of 11/1/

17 Top Challenges in GDUFA II Fees CMO fee Not clear how many facilities would qualify Affiliations with sponsors Generic Drug Applicant Program Fee Unknown affiliations Inactive ANDAs Portfolio adjustments 17

18 Generic Drug Applicant Program Fee Each person and its affiliates will be assessed an annual fee depending on the number of approved ANDAs in its (their) combined portfolio. There are three tiers: Large: 20 or more approved ANDAs Medium: Between 6 and 19 approved ANDAs Small: Five or fewer approved ANDAs The fee for each tier differs: Large: Full fee Medium: 40% of the large fee Small: 10% of the large fee 18

19 How We Tackled It Two-Phase Approach Reach-out to industry Correct data quality issues Iterative posting of and updates to data Made adjustments for: Undeclared affiliations Inactive ANDAs Potential portfolio adjustments 19

20 What We Found Tier Raw Data After Cleanup After Adjustments Large Medium Small Total Note: The numbers in the After Adjustments column and the FY2018 fees calculated from them were published in the Federal Register of August 29,

21 How Did This Compare to Go-Live? Tier Posted FY 2018 Fees As of If We Had Known Delta Large 62 $1,590, $1,582, % Medium 52 $636, $632, % Small 258 $159, $158, % Total An estimation delta of around one-half of one percent is exceptional, and shows that the hard work of staff on both industry s and the Agency s side really paid off. 21

22 Going Forward The ANDA holder list will be updated on our website For now, updates will reflect only those changes that affect the current FY fees Next year s process will be much less work Early in calendar 2018 we will post the initial ANDA holder list April 1, 2018 is the deadline for withdrawal requests and affiliate updates August 2018 is when FY2019 fees will be posted 22

23 GDUFA User Fee Rates, FY2018 GDUFA Fee Types FY 2018 ANDA $171,823 DMF $47,829 Program Fee Facility Large Size $1,590,792 Medium Size $636,317 Small Size $159,079 Domestic API $45,367 Foreign API $60,367 Domestic FDF $211,087 Foreign FDF $226,087 Domestic CMO $70,362 Foreign CMO $85,362 Backlog $17,434 23

24 Further Information Link to FDA site where program fee data (including FY2018 fee rates) are posted: /gdufa. Link to a webinar we gave in October going over this information: Oct mp4 Recently-issued guidance on GDUFA II user fees: tion/guidances/ucm pdf Contact us at: CDERCollections@fda.hhs.gov

25

Status Update on the Review of DMFs

Status Update on the Review of DMFs Status Update on the Review of DMFs Presented by Dave Skanchy, Ph.D. Director DMF Review Staff GPhA/FDA CMC Workshop June 4, 2013 1 Outline Changes to the DMF Review Staff: Update on GDUFA hiring and the

More information

Proper CMC Submission -API. Ramnarayan Randad, Ph.D. DMF Review Staff/OGD June 4, 2014 GPhA/FDA Bethesda, MD

Proper CMC Submission -API. Ramnarayan Randad, Ph.D. DMF Review Staff/OGD June 4, 2014 GPhA/FDA Bethesda, MD Proper CMC Submission -API Ramnarayan Randad, Ph.D. DMF Review Staff/OGD June 4, 2014 GPhA/FDA Bethesda, MD 1 Type II Drug Master Files (DMFs) and GDUFA Generic Drug User Fee Amendments (GDUFA) July 9,

More information

GDUFA: 2 ½ years later Impact & Importance

GDUFA: 2 ½ years later Impact & Importance GDUFA: 2 ½ years later Impact & Importance Georgia Hizon Manager, Regulatory Publications Fresenius Kabi USA, LLC Disclaimer The views and opinions expressed in the following PowerPoint slides are those

More information

Generic Drug User Fee Amendments of 2012; Regulatory Science Initiatives; Public Hearing;

Generic Drug User Fee Amendments of 2012; Regulatory Science Initiatives; Public Hearing; 4160-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Part 15 [Docket No. FDA-2013-N-0402] Generic Drug User Fee Amendments of 2012; Regulatory Science Initiatives; Public

More information

Alignment of FSMA with Existing Food Safety Programs International Citrus & Beverage Conference

Alignment of FSMA with Existing Food Safety Programs International Citrus & Beverage Conference Alignment of FSMA with Existing Food Safety Programs International Citrus & Beverage Conference Donald Kautter US Food and Drug Administration Center for Food Safety and Applied Nutrition Office of Food

More information

Chapter 15 Section 1

Chapter 15 Section 1 Chapter 15 Section 1 Issue Date: November 6, 2007 Authority: 32 CFR 199.14(a)(3) and (a)(6)(ii) 1.0 APPLICABILITY This policy is mandatory for the reimbursement of services provided either by network or

More information

ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry

ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments

More information

ANDA Filing and Refuse to Receive Issues. Johnny Young, M.A.L.A.

ANDA Filing and Refuse to Receive Issues. Johnny Young, M.A.L.A. ANDA Filing and Refuse to Receive Issues Johnny Young, M.A.L.A. 1 Statistics 2 497 ANDAs Refused-for-Receipt between CYs 2009-2012: - 12% (2009) - 18% (2010) - 15.5% (2011) - 9.4% (2012) 3 For 2012, 100

More information

Teva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs 425 Privet Road Horsham, PA 19044

Teva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs 425 Privet Road Horsham, PA 19044 DEPARTMENT OF HEALTH & HUMAN SERVICES ANDA 090783 Food and Drug Administration Silver Spring, MD 20993 Teva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs

More information

Completeness Assessments for Type II API DMFs Under GDUFA Guidance for Industry

Completeness Assessments for Type II API DMFs Under GDUFA Guidance for Industry Completeness Assessments for Type II API DMFs Under GDUFA Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

More information

SUPPORTING SCHOOLS AND STUDENTS TO ACHIEVE SHERRI YBARRA, SUPERINTENDENT OF PUBLIC INSTRUCTION

SUPPORTING SCHOOLS AND STUDENTS TO ACHIEVE SHERRI YBARRA, SUPERINTENDENT OF PUBLIC INSTRUCTION SUPPORTING SCHOOLS AND STUDENTS TO ACHIEVE Director s Webinar August 15, 2017 Special Education Team Idaho State Dept. of Education Agenda 1. New Directors 2. Guidance Document Revisions 3. General Updates

More information

Public Policy HCA Public Policy No

Public Policy HCA Public Policy No Public Policy HCA Public Policy No.11-2016 TO: FROM: RE: HCA HOSPICE PROVIDER MEMBERS PATRICK CONOLE, VICE PRESIDENT, FINANCE & MANAGEMENT UPDATES FROM NGS HOSPICE ADVISORY MEETING DATE: JUNE 10, 2016

More information

Risk-Based CMC ANDA Review

Risk-Based CMC ANDA Review Risk-Based CMC ANDA Review Andre Raw*, PhD Director Division of Chemistry I FDA-CDER- Office of Generic Drugs andre.raw@fda.hhs.gov *This presentation reflects the views of the author and should not be

More information

Guidance for Industry ANDA Submissions Refuse-to-Receive Standards

Guidance for Industry ANDA Submissions Refuse-to-Receive Standards Guidance for Industry ANDA Submissions Refuse-to-Receive Standards DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document

More information

CDER Compliance Update

CDER Compliance Update CDER Compliance Update Douglas Stearn, JD Deputy Director for Policy and Analysis FDA/CDER/Office of Compliance FDLI Enforcement, Litigation and Compliance Conference Washington, DC December 12, 2012 1

More information

Guidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

Guidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only. Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry DRAFT GUIDANCE This guidance

More information

Office of Clinical Research Annual Report 2017 July 1, June 30, 2017

Office of Clinical Research Annual Report 2017 July 1, June 30, 2017 Office of Clinical Research Annual Report 2017 July 1, 2016- June 30, 2017 Table of Contents Title Page Number Mission Statement 1 Objective 1 Research Services 1 Research Highlights 2 Figure 1 Number

More information

FDLI s Enforcement, Litigation, and Compliance Conference. Center for Tobacco Products Office of Compliance and Enforcement 2017 Update

FDLI s Enforcement, Litigation, and Compliance Conference. Center for Tobacco Products Office of Compliance and Enforcement 2017 Update FDLI s Enforcement, Litigation, and Compliance Conference Center for Tobacco Products Office of Compliance and Enforcement 2017 Update Ann Simoneau, Director Office of Compliance and Enforcement Center

More information

Guidance for Municipalities Regarding Marijuana for Adult Use January 2018

Guidance for Municipalities Regarding Marijuana for Adult Use January 2018 Guidance for Municipalities Regarding Marijuana for Adult Use January 2018 The following information is provided to assist municipalities by addressing questions related to the regulation of marijuana

More information

Withdrawal of Proposed Rule on Supplemental Applications Proposing Labeling Changes for

Withdrawal of Proposed Rule on Supplemental Applications Proposing Labeling Changes for This document is scheduled to be published in the Federal Register on 12/14/2018 and available online at https://federalregister.gov/d/2018-27098, and on govinfo.gov 4164-01-P DEPARTMENT OF HEALTH AND

More information

WHEREAS, the Tennessee General Assembly finds that thousands of Tennesseans are

WHEREAS, the Tennessee General Assembly finds that thousands of Tennesseans are AN ACT to license sign language interpreters WHEREAS, the Tennessee General Assembly finds that thousands of Tennesseans are individuals who are Deaf, Deaf-Blind, or Hard of Hearing; and WHEREAS, the General

More information

STATE OF NEW JERSEY DEPARTMENT OF CORRECTIONS. Medication Assisted Treatment For Substance Use Disorder In the New Jersey County Jails

STATE OF NEW JERSEY DEPARTMENT OF CORRECTIONS. Medication Assisted Treatment For Substance Use Disorder In the New Jersey County Jails STATE OF NEW JERSEY DEPARTMENT OF CORRECTIONS Medication Assisted Treatment For Substance Use Disorder In the New Jersey County Jails NOTICE OF GRANT OPPORTUNITY (Updated) Announcement Date: September

More information

32 CFR (a)(4), (a)(6)(iii), and (a)(6)(iv)

32 CFR (a)(4), (a)(6)(iii), and (a)(6)(iv) CHAPTER 15 SECTION 1 ISSUE DATE: November 6, 2007 AUTHORITY: 32 CFR 199.14(a)(4), (a)(6)(iii), and (a)(6)(iv) I. APPLICABILITY This policy is mandatory for the reimbursement of services provided either

More information

CHAPTER 7 SECTION 24.1 PHASE I, PHASE II, AND PHASE III CANCER CLINICAL TRIALS TRICARE POLICY MANUAL M, AUGUST 1, 2002 MEDICINE

CHAPTER 7 SECTION 24.1 PHASE I, PHASE II, AND PHASE III CANCER CLINICAL TRIALS TRICARE POLICY MANUAL M, AUGUST 1, 2002 MEDICINE MEDICINE CHAPTER 7 SECTION 24.1 ISSUE DATE: AUTHORITY: 32 CFR 199.4(e)(26) I. DESCRIPTION The Department of Defense (DoD) Cancer Prevention and Treatment Clinical Trials Demonstration was conducted from

More information

510(k) submissions. Getting US FDA clearance for your device: Improving

510(k) submissions. Getting US FDA clearance for your device: Improving Getting US FDA clearance for your device: Improving 510(k) submissions Audrey Swearingen, RAC Director, Regulatory Affairs Telephone: +1 512.222.0263 Email: aswearingen@emergogroup.com Download this white

More information

Corporate Policies. Corporate Billing and Collection Policy Section:

Corporate Policies. Corporate Billing and Collection Policy Section: MedStar Health Title: Purpose: Corporate Policies Corporate Billing and Collection Policy Section: To ensure uniform management of the MedStar Health Corporate Billing and Collection Program for all MedStar

More information

Municipal Guidance CONTACTING THE COMMISSION. 101 Federal Street, 13 th Floor Boston, MA Phone: (617) Fax: (617)

Municipal Guidance CONTACTING THE COMMISSION. 101 Federal Street, 13 th Floor Boston, MA Phone: (617) Fax: (617) Municipal Guidance UPDATED MARCH, 2018 The following information is provided to assist municipalities by addressing questions related to the regulation of marijuana establishments. Additional information

More information

RESULTS AT A GLANCE. FDA Oversight of Tobacco Manufacturing Establishments. HHS OIG Data Brief August 2017 OEI

RESULTS AT A GLANCE. FDA Oversight of Tobacco Manufacturing Establishments. HHS OIG Data Brief August 2017 OEI HHS OIG Data Brief August 2017 OEI-01-15-00300 FDA Oversight of Tobacco Manufacturing Establishments RESULTS AT A GLANCE The Tobacco Control Act authorized FDA to regulate domestic tobacco manufacturers

More information

OFFICE OF PHARMACEUTICAL SCIENCES. COVER FORM FOR THE TECHNICAL REVIEW OF DRUG MASTER FILES (DMFs) CONTENTS

OFFICE OF PHARMACEUTICAL SCIENCES. COVER FORM FOR THE TECHNICAL REVIEW OF DRUG MASTER FILES (DMFs) CONTENTS MANUAL OF POLICIES AND PROCEDURES CENTER FOR DRUG EVALUATION AND RESEARCH MAPP 5015.3 OFFICE OF PHARMACEUTICAL SCIENCES COVER FORM FOR THE TECHNICAL REVIEW OF DRUG MASTER FILES (DMFs) CONTENTS PURPOSE

More information

Licensure Portability Resource Guide FSBPT. Ethics & Legislation Committee Foreign Educated Standards 12/17/2015

Licensure Portability Resource Guide FSBPT. Ethics & Legislation Committee Foreign Educated Standards 12/17/2015 2015 Licensure Portability Resource Guide FSBPT Ethics & Legislation Committee Foreign Educated Standards 12/17/2015 Licensure Portability Resource Guide Introduction In the current health care environment,

More information

2014 FDA/JIFSAN Food & Nutrition Webinar

2014 FDA/JIFSAN Food & Nutrition Webinar 2014 FDA/JIFSAN Food & Nutrition Webinar Medical Foods Shawne Suggs-Anderson, MMSc, _ RD Infant Formula and Medical Foods Staff ONLDS/CFSAN/FDA September 23, 2014 53 Main Objectives History What is a Medical

More information

Agency Information Collection Activities; Submission for Office of Management and

Agency Information Collection Activities; Submission for Office of Management and This document is scheduled to be published in the Federal Register on 02/19/2019 and available online at https://federalregister.gov/d/2019-02596, and on govinfo.gov 4164-01-P DEPARTMENT OF HEALTH AND

More information

AURORA HEALTH CARE BETTER TOGETHER FUND Sexual Assault and Domestic Violence Prevention Community Advocacy Agencies Request for Proposal

AURORA HEALTH CARE BETTER TOGETHER FUND Sexual Assault and Domestic Violence Prevention Community Advocacy Agencies Request for Proposal AURORA HEALTH CARE BETTER TOGETHER FUND Sexual Assault and Domestic Violence Prevention Community Advocacy Agencies Request for Proposal For more than 25 years, Aurora Health Care has been at the forefront

More information

Pharmacogenomic Testing for Warfarin Response (NCD 90.1)

Pharmacogenomic Testing for Warfarin Response (NCD 90.1) Policy Number 90.1 Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 01/08/2014 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable to UnitedHealthcare

More information

CENTRAL FLORIDA CARES HEALTH SYSTEM, INC. Opioid State Targeted Response (STR) FY Proposal Instructions

CENTRAL FLORIDA CARES HEALTH SYSTEM, INC. Opioid State Targeted Response (STR) FY Proposal Instructions CENTRAL FLORIDA CARES HEALTH SYSTEM, INC. Opioid State Targeted Response (STR) FY 2017-2018 Proposal Instructions May 26, 2017 Table of Contents I. INTRODUCTION... 2 II. GENERAL PROPOSAL INSTRUCTIONS AND

More information

DEPARTMENT OF VETERANS AFFAIRS SUMMARY: The Department of Veterans Affairs (VA) is amending its medical

DEPARTMENT OF VETERANS AFFAIRS SUMMARY: The Department of Veterans Affairs (VA) is amending its medical This document is scheduled to be published in the Federal Register on 03/23/2017 and available online at https://federalregister.gov/d/2017-05799, and on FDsys.gov DEPARTMENT OF VETERANS AFFAIRS 8320-01

More information

Hospice Quality Reporting Program Provider Training

Hospice Quality Reporting Program Provider Training Hospice Quality Reporting Program Provider Training Hospice Quality Reporting Program (HQRP) Data Submission and Requirements Presenters: Brenda Karkos, M.S.N./M.B.A., R.N., CHPN, Nurse Researcher/Associate,

More information

GENERAL INFORMATION AND INSTRUCTIONS

GENERAL INFORMATION AND INSTRUCTIONS NON-PARTICIPATING MANUFACTURER CERTIFICATION FOR LISTING ON OREGON DIRECTORY GENERAL INFORMATION AND INSTRUCTIONS Who is required to file this Certification? Any tobacco product manufacturer who is a non-participating

More information

Coventry Health Care of Georgia, Inc.

Coventry Health Care of Georgia, Inc. Coventry Health Care of Georgia, Inc. PRESCRIPTION DRUG RIDER (for High Deductible Health Plans) This Prescription Drug Rider is an attachment to the Coventry Health Care of Georgia, Inc. ( Health Plan

More information

Final Rule for Preventive Controls for Animal Food

Final Rule for Preventive Controls for Animal Food Final Rule for Preventive Controls for Animal Food http://www.fda.gov/fsma THE FUTURE IS NOW 1 Background Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food

More information

Medicare Part D Overutilization Monitoring System

Medicare Part D Overutilization Monitoring System Medicare Part D Overutilization Monitoring System Lisa Thorpe, Division of Part D Policy Gary Wirth, Division of Clinical and Operational Performance Medicare Drug Benefit and C&D Data Group July 17, 2013

More information

IBCSOMS Certificate of Added Qualification Handbook

IBCSOMS Certificate of Added Qualification Handbook IBCSOMS Certificate of Added Qualification Handbook TABLE OF CONTENTS IMPORTANT: The enclosed Rules and Procedures are specific to initial Subspecialty Certification in Head and Neck Oncologic and Reconstructive

More information

DF/HCC Principal Research Doctor / Institution: Irene Ghobrial, MD / DFCI

DF/HCC Principal Research Doctor / Institution: Irene Ghobrial, MD / DFCI Protocol Title: Study of Precursor Hematological Malignancies to Assess the Relationship between Molecular Events of Progression and Clinical Outcome DF/HCC Principal Research Doctor / Institution: Irene

More information

Request for Proposals (RFP) for School-Based Screening, Brief Intervention, and Referral to Treatment (SBIRT) Services

Request for Proposals (RFP) for School-Based Screening, Brief Intervention, and Referral to Treatment (SBIRT) Services Request for Proposals (RFP) for School-Based Screening, Brief Intervention, and Referral to Treatment (SBIRT) Services As issued by Montgomery County Alcohol, Drug Addiction and Mental Health Services

More information

SAINT LOUIS UNIVERSITY. Applicants to the Graduate Program in Endodontics. Program Requirements

SAINT LOUIS UNIVERSITY. Applicants to the Graduate Program in Endodontics. Program Requirements SAINT LOUIS UNIVERSITY TO: FROM: SUBJECT: Applicants to the Graduate Program in Endodontics Center for Advanced Dental Education Program Requirements 3320 Rutger Street Dreiling-Marshall Hall St. Louis,

More information

OHIO LEGISLATIVE SERVICE COMMISSION

OHIO LEGISLATIVE SERVICE COMMISSION OHIO LEGISLATIVE SERVICE COMMISSION Joseph Rogers and other LSC staff Fiscal Note & Local Impact Statement Bill: H.B. 117 of the 132nd G.A. Sponsor: Reps. Huffman and Brenner Status: As Introduced Local

More information

ASSEMBLY COMMITTEE ON HUMAN SERVICES Blanca Rubio, Chair AB 2702 (McCarty) As Amended April 2, 2018

ASSEMBLY COMMITTEE ON HUMAN SERVICES Blanca Rubio, Chair AB 2702 (McCarty) As Amended April 2, 2018 Page 1 Date of Hearing: April 24, 2018 SUBJECT: Trustline registry. ASSEMBLY COMMITTEE ON HUMAN SERVICES Blanca Rubio, Chair AB 2702 (McCarty) As Amended April 2, 2018 SUMMARY: Requires the Department

More information

Funding Chapter Programs. San Antonio 2001 Chapter Chairs Workshop

Funding Chapter Programs. San Antonio 2001 Chapter Chairs Workshop Funding Chapter Programs Objectives Outline strategies and methods of funding Chapter activities Share experiences Document ideas for funding Document ways IEEE/COMSOC could help the Chapters Activities

More information

ASSOCIATE MEMBERSHIP. Benefits and Services OVER THIRTY YEARS, ONE VOICE!

ASSOCIATE MEMBERSHIP. Benefits and Services OVER THIRTY YEARS, ONE VOICE! OVER HIRY YEARS, ONE VOICE! ASSOCIAE MEMBERSHIP Benefits and Services 925 L Street, Suite 1200 Sacramento, CA 95814 el: (916) 662-7213 Fax: (916) 443-7468 www.ssda.org About SSDA I n 1983, the Small School

More information

Office of Generic Drugs. April 14, 2010

Office of Generic Drugs. April 14, 2010 Considerations for PET ANDAs Office of Generic Drugs April 14, 2010 1 Agenda Office of Generic Drugs: background information RLDs and Suitability Petitions Submission requirements for an ANDA Approval

More information

BARBARA AVED ASSOCIATES

BARBARA AVED ASSOCIATES BARBARA AVED ASSOCIATES April 2018 Table of Contents INTRODUCTION... 2 METHODS... 3 FINDINGS... 4 I. Extent of Emergency Department Use for Preventable Dental Conditions... 4 II. Utilization of Dental

More information

TOBACCO PRODUCT OR MEDICAL PRODUCT?

TOBACCO PRODUCT OR MEDICAL PRODUCT? TOBACCO PRODUCT OR MEDICAL PRODUCT? Priscilla Callahan-Lyon, MD Deputy Director Division of Individual Health Science Office of Science, CTP Grail Sipes, JD Director Office of Regulatory Policy, CDER Disclaimer:

More information

DEPARTMENT OF VETERANS AFFAIRS SUMMARY: The Department of Veterans Affairs (VA) proposes to amend its medical

DEPARTMENT OF VETERANS AFFAIRS SUMMARY: The Department of Veterans Affairs (VA) proposes to amend its medical This document is scheduled to be published in the Federal Register on 08/05/2016 and available online at http://federalregister.gov/a/2016-18660, and on FDsys.gov DEPARTMENT OF VETERANS AFFAIRS 8320-01

More information

Chapter Affiliation Requirements Workbook

Chapter Affiliation Requirements Workbook 2019 Chapter Affiliation Requirements Workbook Association for Talent Development (ATD) Chapter Services Dear Chapter Leader, Welcome to the 2019 CARE Planning Workbook, a guiding tool for chapters to

More information

2019 Sponsorship Program

2019 Sponsorship Program 2019 Sponsorship Program Winter Conference March 5 6 The RiverCentre St Paul, MN Day with the Payers May 16 Earle Brown Heritage Center Brooklyn Center, MN Summer Conference July 17 19 Duluth Entertainment

More information

NJAMHAA s IT PRoject 2018 Annual Conference INVASION. of the Pines Manor Edison NJ. Sponsorship, Exhibiting and Advertising Opportunities

NJAMHAA s IT PRoject 2018 Annual Conference INVASION. of the Pines Manor Edison NJ. Sponsorship, Exhibiting and Advertising Opportunities NJAMHAA s IT PRoject 2018 Annual Conference INVASION of the 3.7.18 Pines Manor Edison NJ Sponsorship, Exhibiting and Advertising Opportunities About The NJAMHAA IT Project The Information Technology Project

More information

OTC Drug Monograph Reform FDLI Annual Conference May 4, 2018

OTC Drug Monograph Reform FDLI Annual Conference May 4, 2018 OTC Drug Monograph Reform FDLI Annual Conference May 4, 2018 Elizabeth Jungman Director, Public Health Programs, The Pew Charitable Trusts, and Member, FDLI Board of Directors David C. Spangler Senior

More information

Self-Evaluation and Attestation

Self-Evaluation and Attestation Legal Provider Name: Agreement No(s): Please submit this completed document with accompanying documentation by: Respond to all statements by placing a checkmark in the applicable box in the Provider Response

More information

Primer: Medical Device User Fee Amendments Han Zhong l September 2011

Primer: Medical Device User Fee Amendments Han Zhong l September 2011 Primer: Medical Device User Fee Amendments Han Zhong l September 2011 Introduction The Medical Device User Fee and Modernization Act (MDUFMA or MDUFA) is a set of agreements between the Food and Drug Administration

More information

Chapter 18 Section 2. EXPIRED - Department Of Defense (DoD) Cancer Prevention And Treatment Clinical Trials Demonstration

Chapter 18 Section 2. EXPIRED - Department Of Defense (DoD) Cancer Prevention And Treatment Clinical Trials Demonstration s And Pilot Projects Chapter 18 Section 2 EXPIRED - Department Of Defense (DoD) Cancer Prevention And Treatment Clinical Trials 1.0 PURPOSE The purpose of this demonstration is to improve TRICARE-eligible

More information

Effective and Compliance Dates Applicable to Retailers, Manufacturers, Importers, and Distributors of Newly Deemed Tobacco Products

Effective and Compliance Dates Applicable to Retailers, Manufacturers, Importers, and Distributors of Newly Deemed Tobacco Products Effective and Compliance Dates Applicable to Retailers, Manufacturers, Importers, and Distributors of Newly Deemed Tobacco Quick Facts Retailers that mix and prepare e-liquids or create or modify vaporizers

More information

What's Important to Consider When Developing a Complex Generic Drug? September 5, 2018

What's Important to Consider When Developing a Complex Generic Drug? September 5, 2018 What's Important to Consider When Developing a Complex Generic Drug? September 5, 2018 Session Description FDA has provided drug manufacturers tools to assist the development of complex generic drugs to

More information

Quality Payment Program: A Closer Look at the Proposed Rule for Year 3

Quality Payment Program: A Closer Look at the Proposed Rule for Year 3 Quality Payment Program: A Closer Look at the Proposed Rule for Year 3 Sandy Swallow and Michelle Brunsen August 21, 2018 1 This material was prepared by Telligen, the Medicare Quality Innovation Network

More information

Research on the Administrative Rules of APIs, Pharmaceutical Excipients and Auxiliary Materials Master File. Translation version

Research on the Administrative Rules of APIs, Pharmaceutical Excipients and Auxiliary Materials Master File. Translation version Research on the Administrative Rules of APIs, Pharmaceutical Excipients and Auxiliary Materials Master File Division of Pharmaceuticals Department of Drug Registration Hou Renping Translation version Main

More information

Criteria and Application for Men

Criteria and Application for Men Criteria and Application for Men Return completed form via fax or email to LIVESTRONG Foundation attn LIVESTRONG Fertility Fax 512.309.5515 email Cancer.Navigation@LIVESTRONG.org Made possible by participating

More information

Request for Proposals for a Clean Syringe Exchange Program

Request for Proposals for a Clean Syringe Exchange Program ANNA M. ROTH, RN, MS, MPH HEALTH SERVICES DIRECTOR DAN PEDDYCORD, RN, MPA/HA DIRECTOR OF PUBLIC HEALTH C O N T R A C O S T A P U B L I C H E A L T H 597 CENTER AVENUE, SUITE 200 MARTINEZ, CALIFORNIA 94553

More information

Inpatient Psychiatric Facility Quality Reporting (IPFQR) Program

Inpatient Psychiatric Facility Quality Reporting (IPFQR) Program FY 2017 IPPS Final Rule IPFQR Changes, APU Determination and Reconsideration Review Questions and Answers Moderator/Speaker: Evette Robinson, MPH Project Lead, IPFQR Inpatient Hospital Value, Incentives,

More information

Cancer Immunotherapy Pilot Program/ Patents 4 Patients. USPTO BCP Customer Partnership Meeting Alexandria, VA August 2, 2017

Cancer Immunotherapy Pilot Program/ Patents 4 Patients. USPTO BCP Customer Partnership Meeting Alexandria, VA August 2, 2017 Cancer Immunotherapy Pilot Program/ Patents 4 Patients USPTO BCP Customer Partnership Meeting Alexandria, VA August 2, 2017 1 Cancer Immunotherapy Pilot Program/ Patents 4 Patients The United States Patent

More information

Chapter Affiliation Annual Report Workbook

Chapter Affiliation Annual Report Workbook 2017 Chapter Affiliation Annual Report Workbook International Association of Workforce Professionals 3267 Bee Caves Road Suite 107-104 Austin, Texas 78746 info@iawponline.org Phone 1-888-898-9960 Letter

More information

Marijuana Legalization Update

Marijuana Legalization Update Marijuana Legalization Update PJ McCann, Esq. Deputy General Counsel February 14, 2018 1 Context Many moving parts in Cannabis Control Commission (CNB) regulatory process Information and recommendations

More information

Dental Public Health Activities & Practices

Dental Public Health Activities & Practices Dental Public Health Activities & Practices Practice Number: 25001 Submitted By: Michigan Department of Community Health Submission Date: May 2002 Last Updated: June 2010 Name of the Practice: Healthy

More information

Family Smoking Prevention and Tobacco Control Act. Comments regarding crop protection agents

Family Smoking Prevention and Tobacco Control Act. Comments regarding crop protection agents Family Smoking Prevention and Tobacco Control Act (PUBLIC LAW 111-31 JUNE 22, 2009) Comments regarding crop protection agents Presentation Objectives What is the intent of FDA in regulating CPAs? What

More information

Issue Brief. Eliminating Adult Dental Benefits in Medi-Cal: An Analysis of Impact. Introduction. Background

Issue Brief. Eliminating Adult Dental Benefits in Medi-Cal: An Analysis of Impact. Introduction. Background Eliminating Adult Dental Benefits in Medi-Cal: An Analysis of Impact Introduction In 2009, California eliminated non-emergency dental services for adults in its Medicaid program, Medi-Cal. The California

More information

FACILITATOR TRAINING. TO REGISTER See pages 2-7 for more information and to register

FACILITATOR TRAINING. TO REGISTER See pages 2-7 for more information and to register FACILITATOR TRAINING DATES & LOCATIONS Wednesday, September 14, 2016 Chicago, IL Wednesday, November 9, 2016 Springfield, IL Wednesday, November 16, 2016 Chicago, IL* Wednesday, March 15, 2017 Chicago,

More information

Nevertheless, NSP grantees may retain some or all program income in the NSP program;

Nevertheless, NSP grantees may retain some or all program income in the NSP program; FREQUENTLY ASKED QUESTIONS REGARDING THE TRANSFER OF NEIGHBORHOOD STABILIZATION PROGRAM (NSP) PROGRAM INCOME U.S. Department of Housing and Urban Development Office of Community Planning and Development

More information

Dental PPO Plan. A plan to help you pay for the dental care you need. Accident & Health

Dental PPO Plan. A plan to help you pay for the dental care you need. Accident & Health Dental PPO Plan A plan to help you pay for the dental care you need National General Accident and Health markets products underwritten by Time Insurance Company, National Health Insurance Company, Integon

More information

Phase I Planning Grant Application. Issued by: Caring for Colorado Foundation. Application Deadline: July 1, 2015, 5:00 PM

Phase I Planning Grant Application. Issued by: Caring for Colorado Foundation. Application Deadline: July 1, 2015, 5:00 PM Phase I Planning Grant Application Issued by: Caring for Colorado Foundation Application Deadline: July 1, 2015, 5:00 PM Executive Summary Caring for Colorado is currently accepting applications for SMILES

More information

Presentation to the NCSL Fiscal Analysts Seminar, October 2014

Presentation to the NCSL Fiscal Analysts Seminar, October 2014 Presentation to the NCSL Fiscal Analysts Seminar, October 2014 1 Results First in New Mexico Implementation Use of Results First in Work of LFC Lessons learned 2 Established in 1957 Non-partisan legislative

More information

Final Rules Preventive Controls for Human Food Preventive Controls for Animal Food

Final Rules Preventive Controls for Human Food Preventive Controls for Animal Food Final Rules Preventive Controls for Human Food Preventive Controls for Animal Food http://www.fda.gov/fsma THE FUTURE IS NOW 1 Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive

More information

TPE Company Update. 1 November TPI Enterprises Ltd ABN

TPE Company Update. 1 November TPI Enterprises Ltd ABN TPE Company Update 1 November 2017 TPI Enterprises Ltd ABN 26 107 872 453 1 Contents Achievements 3 TPE Background 4 Q3 Highlights & Key Focuses 9 US Opioid Media Coverage 14 Acquisition Update 16 Agricultural

More information

January To: All Local CRN CHAPTERS

January To: All Local CRN CHAPTERS To: All Local CRN CHAPTERS January 2011 Re: Policies and Procedures for Operation as an Affiliated Local Chapter of the National Kidney Foundation s Council on Renal Nutrition (NKF-CRN) and new Local Chapter

More information

SAl N T UNIVERSITY. LO U I S TO: Applicants to the Graduate Program in Endodontics ADVANCED DENTAL EDUCATION

SAl N T UNIVERSITY. LO U I S TO: Applicants to the Graduate Program in Endodontics ADVANCED DENTAL EDUCATION SAl N T UNIVERSITY EST. 7818 LO U I S TO: Applicants to the Graduate Program in Endodontics FROM: Center for Advanced Dental Education CENTER FOR ADVANCED DENTAL EDUCATION Graduate Program in Endodontics

More information

Sport and Exercise Science Undergraduate Practicum Application Packet Instructions

Sport and Exercise Science Undergraduate Practicum Application Packet Instructions Sport and Exercise Science Undergraduate Practicum Application Packet Instructions Please read the ENTIRE instructions and information sheets carefully for complete directions and information before completing

More information

2018 Business Associate Sponsorship Options

2018 Business Associate Sponsorship Options 2018 Business Associate Sponsorship Options P.O. Box 790 - Sherwood, OR 97140 Phone (678) 523-5915 - Fax (877) 872-3493 - Email: main@ohiomgma.com - www.ohiomgma.com members are healthcare leaders and

More information

Report on FY2015 Annual User Satisfaction Survey on Patent Examination Quality

Report on FY2015 Annual User Satisfaction Survey on Patent Examination Quality Report on FY2015 Annual User Satisfaction Survey on Patent Examination Quality June 2016 Japan Patent Office ABSTRACT I. Introduction Globally reliable high-quality patent examination and proper patent-granting

More information

Financial Administration and Control of Research and Special Funds

Financial Administration and Control of Research and Special Funds 1 2 3 Financial Administration and Control of Research and Special Funds 4 Financial Administration and Control of Research and Special Funds Presenter Name Colin Nicolson Presenter Title Assistant Manager

More information

UNITED STATES REGULATION OF TOBACCO PRODUCTS. Presented by Mitch Zeller Center Director FDA Center for Tobacco Products

UNITED STATES REGULATION OF TOBACCO PRODUCTS. Presented by Mitch Zeller Center Director FDA Center for Tobacco Products UNITED STATES REGULATION OF TOBACCO PRODUCTS Presented by Mitch Zeller Center Director FDA Center for Tobacco Products May 24, 2016 OVERVIEW OF TODAY S PRESENTATION Highlights of the Deeming Final Rule

More information

Cannabis Retail Regulation and Licence Applications PART 1 NOVEMBER 27, 2018

Cannabis Retail Regulation and Licence Applications PART 1 NOVEMBER 27, 2018 Cannabis Retail Regulation and Licence Applications PART 1 NOVEMBER 27, 2018 Speakers from the AGCO Phil Serruya (Panel Moderator) Director, Communications Tom Mungham Chief Operating Officer Brent McCurdy

More information

EDITION SPECIAL INSIDE

EDITION SPECIAL INSIDE SUMMER 2008 Increase in Utilization of Crown Build-ups and Changes in Utilization Following an Audit Credentialing Tips and Reminders Online Fee Filing SPECIAL DELTA DENTAL OF MINNESOTA EDITION INSIDE

More information

Shawn Stevens Food Industry Consultant and Lawyer

Shawn Stevens Food Industry Consultant and Lawyer Shawn Stevens Food Industry Consultant and Lawyer stevens@foodindustrycounsel.com 920.698.2561 COMPLYING WITH FSMA S PREVENTIVE CONTROL RULE AS A SMALL BUSINESS COMPLYING WITH FSMA S PREVENTIVE CONTROL

More information

Business Impact Analysis

Business Impact Analysis ACTION: Final DATE: 05/23/2018 8:24 AM Business Impact Analysis Agency Name: Ohio Department of Medicaid (ODM) Regulation/Package Title: Dental services Rule Number(s): Rule 5160-5-01 with appendices A

More information

Anchor p! All Healthcare Professionals on Deck. April 11-13, Tennessee MGMA 2018 Spring Conference. Park Vista Hotel, Gatlinburg TENNESSEE

Anchor p! All Healthcare Professionals on Deck. April 11-13, Tennessee MGMA 2018 Spring Conference. Park Vista Hotel, Gatlinburg TENNESSEE Anchor p! All Healthcare Professionals on Deck Tennessee MGMA 2018 Spring Conference April 11-13, 2018 Park Vista Hotel, Gatlinburg TENNESSEE TENNESSEE MGMA 2018 SPRING CONFERENCE VENDOR OPPORTUNITIES

More information

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: SOP number: SOP category: Version number: 03 Version date: 19 December 2016 Effective date: 19 January 2017 Revision due date: 19 January 2020 NEWCASTLE CLINICAL TRIALS UNIT STANDARD

More information

2017 Joint Annual Conference Exhibit and Sponsorship Program

2017 Joint Annual Conference Exhibit and Sponsorship Program 2017 Joint Annual Conference Exhibit and Sponsorship Program April 27-28, 2017 Double Tree Chicago Oak Brook, Illinois Don t miss this opportunity to reach your target market. Take advantage of these convenient,

More information

Massachusetts Medicaid pediatric high-risk asthma bundled payment pilot

Massachusetts Medicaid pediatric high-risk asthma bundled payment pilot University of Massachusetts Medical School escholarship@umms Commonwealth Medicine Publications Commonwealth Medicine 9-28-2011 Massachusetts Medicaid pediatric high-risk asthma bundled payment pilot Katharine

More information

Opioid State Targeted Response (STR) Project

Opioid State Targeted Response (STR) Project Opioid State Targeted Response (STR) Project Requirement: Frequency: Due Date: The Office of Substance and Abuse and Mental Health (SAMH) Contract On going On going The major goal of Florida's Opioid State

More information

Telecom Order CRTC

Telecom Order CRTC Telecom Order CRTC 2018-66 PDF version Ottawa, 16 February 2018 File numbers: 1011-NOC2016-0116 and 4754-553 Determination of costs award with respect to the participation of the Deaf Wireless Canada Committee

More information

EMPLOYEE PARKING PASS PROGRAM

EMPLOYEE PARKING PASS PROGRAM Chief Executive Officer LAX Los Angeles World Airports EMPLOYEE PARKING PASS PROGRAM Under the Employee Parking Pass Program (EPP), Los Angeles World Airports (LAWA) offers complimentary and discounted

More information